Association between metabolic syndrome, fatty liver disease, and gastrointestinal tumors: a population-based study with external validation - PubMed
4 hours ago
- #Gastrointestinal Tumors
- #Fatty Liver Disease
- #Metabolic Syndrome
- Metabolic Syndrome (MetS) is strongly associated with higher prevalence of fatty liver disease (FLD) and gastrointestinal tumors (GIT).
- In the development cohort, MetS patients had a FLD prevalence of 16.2% vs. 4.6% in non-MetS, and GIT incidence of 1.25% vs. 0.57%.
- After full adjustment, MetS remained a strong independent risk factor for FLD (OR = 3.889) and GIT (OR = 2.456).
- Validation cohort confirmed these associations with adjusted ORs of 4.760 for FLD and 4.395 for GIT.
- MetS significantly reduced overall survival, with higher HRs for all-cause, cancer-specific, and cardiovascular mortality.
- FLD patients with MetS had even higher all-cause mortality risk (HR = 1.823).
- Sensitivity analysis using IDF criteria confirmed the robustness of the findings.
- Early metabolic intervention is recommended to interrupt progression of liver disease and tumors.